| Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies P Neelakantan, G Gerrard, C Lucas, D Milojkovic, P May, L Wang, ... Blood, The Journal of the American Society of Hematology 121 (14), 2739-2742, 2013 | 113 | 2013 |
| Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy P Neelakantan, D Marin, M Laffan, J Goldman, J Apperley, D Milojkovic Haematologica 97 (9), 1444-1444, 2012 | 46 | 2012 |
| Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy S Booth, J Willan, H Wong, D Khan, R Farnell, A Hunter, T Eyre, H Katz, ... European journal of haematology 105 (4), 476-483, 2020 | 32 | 2020 |
| Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study D Milojkovic, NCP Cross, S Ali, J Byrne, G Campbell, FL Dignan, ... British journal of haematology 192 (1), 62-74, 2021 | 25 | 2021 |
| Combined IL‐6 and JAK/STAT inhibition therapy in COVID‐19‐related sHLH, potential game changer S Portsmore, TNT Nguyen, E Beacham, P Neelakantan British journal of haematology 190 (4), 525, 2020 | 25 | 2020 |
| Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm RA Salisbury, N Curto-Garcia, J O’Sullivan, F Chen, P Polzella, ... Leukemia 35 (8), 2424-2430, 2021 | 12 | 2021 |
| Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. P Neelakantan, K Rezvani, P May, G Gerrard, B Marco, C Paliompeis, ... British journal of haematology 164 (4), 2014 | 6 | 2014 |
| ONLINE ONLY: Breast cancer metastasizing to the tongue P Neelakantan, SR McLean, SK RCN, M Nathan, L Panchal, G Sandhu, ... Canadian Journal of Surgery 51 (3), E63, 2008 | 4 | 2008 |
| The management of myelofibrosis: a British Society for Haematology Guideline DP McLornan, B Psaila, J Ewing, A Innes, S Arami, J Brady, NM Butt, ... British journal of haematology 204 (1), 136-150, 2024 | 3 | 2024 |
| A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study AJ Mead, NM Butt, W Nagi, A Whiteway, S Kirkpatrick, C Rinaldi, ... Therapeutic advances in hematology 13, 20406207221084487, 2022 | 3 | 2022 |
| Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience. F Djebbari, H Hubenov, P Neelakantan, J Wolf, M Offer, A Khera, E Louka, ... British Journal of Haematology 188 (4), 2020 | 2 | 2020 |
| A retrospective real-world study of the current treatment pathways for myelofibrosis in the UK (The REALISM UK Study) AJ Mead, T Somervaille, NM Butt, W Nagi, AJ Whiteway, S Kirkpatrick, ... Blood 134, 1671, 2019 | 2 | 2019 |
| Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib? P Neelakantan, D Milojkovic, G Gerrard, L Foroni, J Apperley, RM Szydlo, ... Blood 120 (21), 3760, 2012 | 2 | 2012 |
| Can the combination of the measurement of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement? P Neelakantan, G Gerrard, L Foroni, D Milojkovic, J Apperley, R Szydlo, ... Blood 120 (21), 68, 2012 | 2 | 2012 |
| The transformative journey of chronic myeloid leukemia P Neelakantan, A Mead International Journal of Hematologic Oncology 7 (1), IJH07, 2018 | 1 | 2018 |
| Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines P Neelakantan, JF Apperley Clinical Practice 10 (3), 283, 2013 | 1 | 2013 |
| Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline DP McLornan, AL Godfrey, A Green, R Frewin, S Arami, J Brady, NM Butt, ... British journal of haematology 204 (1), 127-135, 2024 | | 2024 |
| PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY MNBC Rahimi, P Neelakantan HemaSphere 7 (S3), e38689d1, 2023 | | 2023 |
| Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective … C Gaskell, S Fox, R Fletcher, C Thomas, L Hopkins, A Kumari, ... Blood 138, 1942, 2021 | | 2021 |
| Experience with Pegasys in patients with myeloproliferative neoplasm J Dhanapal, A Mead, P Neelakantan BRITISH JOURNAL OF HAEMATOLOGY 193, 117-117, 2021 | | 2021 |
